Evidence map›Paper›PMID 22683404›Full record

ReviewBiochimica et biophysica acta2012

Circulating tumor cells in the diagnosis and management of pancreatic cancer.

Putao Cen, Xiaoling Ni, Jingxuan Yang, David Y Graham, Min Li

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biochimica et biophysica acta, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03979339 (Feasibility of a New Technology for Isolating Circulating Tumour Cells in Selected Cancer Patients and Healthy Volunteers), which is not on this map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03979339 naunknown statusnot on this mapstarted 2020, after this paper: background citation

Feasibility of a New Technology for Isolating Circulating Tumour Cells in Selected Cancer Patients and Healthy Volunteers

TypeinterventionalSponsorCentre Oscar LambretRan2020 to 2023Enrolled76ConditionsHER2-positive Metastatic Breast Cancer, Ovarian Cancer, Hormone-resistant Prostate Cancer, Circulating Tumor CellArmsBlood sample collection
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Toward a New Era for the Management of Circulating Tumor Cells.Advances in experimental medicine and biology · 2021
    Review
  9. Article
  10. Review
  11. EVALUATING MMP-2 AND TGFß-RI EXPRESSION IN CIRCULATING TUMOR CELLS OF PANCREATIC CANCER PATIENTS AND THEIR CORRELATION WITH CLINICAL EVOLUTION.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2019
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Putao CenDepartment of Internal Medicine, The University of Texas Medical School, Houston, TX 77030, USA.
Xiaoling Ni
Jingxuan Yang
David Y Graham
Min Li
Michael E. DeBakey VA Medical Center · USZhongshan Hospital · CN

Funding

Role of Dietary Zinc Transporter ZIP4 in Pancreatic CancerR01CA138701 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LI, MIN · 2010 to 2015
$1.5M
Roles of Zinc Transporter ZIP4 (SLC39A4) in Pancreatic Cancer PathogenesisR21CA133604 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LI, MIN · 2009 to 2010
$367k
NCI NIH HHS R01 CA138701NCI NIH HHS R01CA138701NCI NIH HHS R21 CA133604NCI NIH HHS R21CA133604
6 · The paper itself

Abstract

Pancreatic cancers are typically resistant to chemo and radiation therapy and are predisposed to distant metastases. Circulating tumor cells (CTCs) are tumor cells disseminated from primary and metastatic sites and can be isolated from peripheral blood. CTC may overcome the limitation of the current available tumor markers, CA19-9. As a surrogate for 'real-time biopsy', CTCs allow recurrent assessment of a tumor's biological activity. We review the current methodologies for CTC extraction and characterization including antibody-based immunological assays, PCR-based assays, and novel technologies based on the physical or biological characteristics of CTCs. CTCs also provide an accessible link to the existence of epithelial to mesenchymal transition, tumor stem cell markers, and ongoing clonal mutations and epigenetic changes in the tumor. We also explore the potential of using CTC profiling in diagnosis, selection of neoadjuvant and adjuvant therapy, detection of recurrent disease, examination of pharmacodynamic biomarkers, as well as in gene therapy and immunotherapy for pancreatic cancer. Ongoing CTC characterization not only has the potential to represent all cells shed from primary pancreatic tumor and each metastatic site, but also allows dynamic sampling at multiple time points during the clinical course to identify the subpopulations of CTCs and the specific molecules driving metastasis and chemo resistance. We predict that CTC genotyping and phenotyping will play an increasing role in personalized therapy and in identification of novel therapeutic targets as well as monitoring the course and status of the disease.

Indexed as

Cell SeparationHumansImmunotherapyNeoplasm MetastasisNeoplastic Cells, CirculatingPancreatic NeoplasmsPrecision Medicine

Identifiers

PMID22683404
PMCPMC3443701
OpenAlexW1966813858

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.